The findings from this investigation subsequently resulted in an extended FDA approval for cemiplimab, allowing its use in combination with platinum‐based chemotherapy as first‐line treatment for patients with advanced NSCLC lacking EGFR, ALK, or ROS1 mutations as of November 2022 [57]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.